Licensed Rights and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2023

Licensed Rights and Other Intangible Assets [Abstract]

Schedule of License Rights and Other Intangible Assets, Net

The following provides information about our license rights and other intangible assets, net (in thousands):

	As of December 31, 2023						As of December 31, 2022
	Gross						Gross
	Carrying		Accumulated				Carrying		Accumulated
	Amount		Amortization		Net		Amount		Amortization		Net
Intangible assets subject to amortization:
Hormone therapy drug patents	$	6,818	$	1,871	$	4,947	$	6,225	$	1,598	$	4,627
Hormone therapy drug patents applied and pending approval		842		—		842		1,995		—		1,995
Intangible assets subject to amortization		7,660		1,871		5,789		8,220		1,598		6,622
Intangible assets not subject to amortization:
Trademarks/trade name rights		309		—		309		321		—		321
Intangible assets, net	$	7,969	$	1,871	$	6,098	$	8,541	$	1,598	$	6,943

Schedule of Intangible Assets Subject To Amortization

Our intangible assets subject to amortization are expected to be amortized as follows (in thousands):

Year ending December 31,
2024		533
2025		445
2026		445
2027		445
2028		445
Thereafter		5,347
Total	$	7,660